Apogee Therapeutics, Inc. (APGE)
After hours:
| Previous close | 21.74 |
| Open | 21.67 |
| Bid | 8.61 x 2900 |
| Ask | 34.41 x 800 |
| Day's range | 20.62 - 22.94 |
| 52-week range | 14.19 - 25.54 |
| Volume | |
| Avg. volume | 372,695 |
| Market cap | 1.088B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 33.00 |
Simply Wall St.We Think Apogee Therapeutics (NASDAQ:APGE) Can Easily Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
GlobeNewswireApogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial PK and safety data from healthy volunteers expected mid-2024; on track to begin Phase 2 in moderate-to-severe atopic dermatitis in 2024 Announcing our finalized nomination of development candidate for APG808, a potentially best-in-class, femtomolar affinity, subcutaneous extended half-life antibody targeting IL-4Rα, a target with clinical validation
- GlobeNewswire
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
SAN FRANCISCO and WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, asthma, chronic obstructive pulmonary disease and other inflammatory and immunology indications, today announced that management will present at the following upcoming investor conferences: Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference Date:
